IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
In tro duc tion
• Larg est ever Jap a nese ac qui si tion
Strategy Statement
Takeda was the world’s num ber 16 phar ma ceu ti cal cor po rate group and re gained its po si tion as Ja pan’s
lead ing phar ma ceu ti cal cor po ra tion ac cord ing to IMS in the year end ing Sep tem ber 2008. Takeda was,
un til re cently, by far the larg est Jap a nese phar ma ceu ti cal com pany but its pre dom i nance was chal lenged
by a wave of con sol i da tion in the Jap a nese in dus try over the past few years push ing it briefly down to sec -
ond place be hind Daiichi Sankyo. The flurry of merger ac tiv ity in the Jap a nese mar ket, which also cre ated
Astellas (Fujisawa and Yamanouchi), Dainippon Sumitomo and Mitsubishi Tanabe Pharma, was driven by
in fil tra tion from for eign firms with healthy pipe lines and mas sive R&D bud gets; Pfizer sat be hind Daiichi
Sankyo as the third lead ing pharmaceutical corporation in Japan in the same period.
Takeda has for many years been re li ant on sales from four lu cra tive global prod ucts: Actos (pioglitazone)
for type 2 di a be tes; the antiulcerant Takepron/Prevacid (lansoprazole); Blopress (candesartan) for hy -
per ten sion and Lupron/Leuplin (leuprorelin) for pros tate can cer. Takeda has faced its main chal lenge to
build strong pipe line can di dates to plug the gap of loom ing pat ent ex pi ra tions of all four foun da tion prod -
ucts over the next five years, some thing that Takeda has been ad dress ing through li cens ing deals and
stra te gic ac qui si tions of prod ucts, tech nol ogy and even com pa nies. Takeda’s big gest ac qui si tion to date,
and the larg est ever ac qui si tion by a Jap a nese Pharma com pany took place in May 2008, of Mil len nium
Pharma, in a Yen1 tril lion deal. As well as ex pand ing its over seas pres ence, Mil len nium pro vides a huge
boost to Takeda’s on col ogy pipe line with a num ber of prom is ing can di dates and its main stay mar keted
prod uct Velcade (bortezomib), an anticancer proteasome in hib i tor, mar keted world wide and in Ja pan by
John son & John son. Also in 2008, Takeda took a 100% stake in Amgen’s Jap a nese sub sid iary via a share
trans fer, while gain ing li cens ing rights to 13 clin i cal (mostly on col ogy) can di dates. This fol lowed a num ber
of stra te gic ac qui si tions over re cent years to boost its pipe line, in clud ing that of Par a digm Ther a peu tics in
2007 and Syrrx in 2005, the lat ter bringing the dipeptidyl peptidase IV (DPP-IV) inhibitor alogliptin (SYR
322), currently awaiting US approval.
With growth hard to find at home, Takeda has had to look to over seas mar kets and has long dis tin guished
it self from other Jap a nese com pa nies in its for ward-think ing over seas ex pan sion pol i cies and will ing ness
to do busi ness with for eign phar ma ceu ti cal com pa nies. Takeda has had a long-stand ing and very suc -
cess ful joint ven ture (TAP Pharmaceuticals) in the USA with Abbott (USA), but the loss of ex clu siv ity for
TAP’s main prod uct, Prevacid (lansoprazole) has re sulted in a de clin ing con tri bu tion from TAP. Af ter 30
years to gether, Takeda de cided to dis solve the jv from mid-2008 and paid $1.5 bil lion for Abbott’s share
of the jv, gain ing full rights to Takepron. The 50% share in TAP will be fully in te grated into Takeda’s grow -
ing stand-alone op er a tion, Takeda Pharmaceuticals North Amer ica (TPNA), through which it is cur rently
pro mot ing Rozerem for in som nia and Actos and in the first half of 2009 will add two new prod ucts:
Kapidex (dexlansoprazole/TAK 390MR), a pro ton pump in hib i tor ap proved in Jan u ary 2009 and Uloric
(fexobustat/TMX 67) for the treat ment of hyperuricemia in pa tients with gout, ap proved in Feb ru ary
2009. Al though Ab bot ob tained rights to Lupron, and re lated as sets as well as all em ploy ees, the move
will, according to Takeda, make it a top 15 US company.
© 2009 IMS Health In cor po rated or its af fil i ates Page 7